As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI1 is the principal inhibitor of urokinase-type plasminogen activator (uPA) and tissue type plasminogen activator (tPA). As important regulators of extracellular matrix remodeling, uPA and PAI 1 play a major role in many processes such as angiogenesis, tumor invasion and obesity. For example, uPA and PAI1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer. The human PAI1 is initially synthesized as 402 amino acid precursor with a Nterminal signal peptide. PAI 1 may exist in one of two possible conformations, designated as active or latent.
該Anti-Human PAI-1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議:Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.